Ncardia has launched a stem cell-derived model of human microglia to advance research into neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), where these cells play an important ...

Moments of daily life with my husband Todd’s ALS frequently put both of us in panic mode. It makes me wonder if we should take more precautions — but there are trade-offs. The other day, for example, ...

New York received the highest mark on the ALS Association’s latest report cards, which grade states based on how effectively they’re using public policy to serve the amyotrophic lateral sclerosis (ALS ...

AB Science will launch a new Phase 3 clinical trial to test its investigational oral therapy masitinib in people with amyotrophic lateral sclerosis (ALS) whose disease is progressing normally and who ...

I was enchanted on the first date with my late husband, Jeff, when our conversation turned to work. It’s an odd thing to say, because we can be conditioned to believe that work should be a less ...

A machine learning analysis of gene activity in spinal cord samples from people with amyotrophic lateral sclerosis (ALS) revealed new genes associated with the neurodegenerative disorder, a study ...

Zydus Lifesciences has been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 2b trial testing its experimental oral treatment usnoflast in people with amyotrophic lateral ...

Last week, I fully intended to write a new “Living Well With ALS” column. I sat down, flipped open my laptop, gazed out the window, and got lost in a stare. As the minutes ticked by, my computer ...

NP001 (sodium chlorite) was associated with a significant survival benefit among a subset of amyotrophic lateral sclerosis (ALS) patients who did not show signs of disease progression when treated ...

A Chicago businessman and philanthropist — David Husman, founder and chairman of Heartland Real Estate Partners — has donated $20 million to advance research into amyotrophic lateral sclerosis (ALS) ...

Alchemab Therapeutics has partnered with Eli Lilly to develop new antibody treatments for amyotrophic lateral sclerosis (ALS) based on an approach that looks at the immune response of those with ...

The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on a Phase 1 clinical trial that’s testing AMX0114, Amylyx Pharmaceuticals’ investigational treatment for amyotrophic lateral ...